Results 31 to 40 of about 14,494 (232)

Weight Changes and Adverse Pregnancy Outcomes With Dolutegravir- and Tenofovir Alafenamide Fumarate-Containing Antiretroviral Treatment Regimens During Pregnancy and Postpartum. [PDF]

Clin Infect Dis
BACKGROUND We evaluated associations between antepartum weight change and adverse pregnancy outcomes and between antiretroviral therapy (ART) regimens and week-50 postpartum body mass index in IMPAACT 2010.
Hoffman RM, Brummel S, Ziemba L, Chinula L, McCarthy K, Fairlie L, Jean-Philippe P, Chakhtoura N, Johnston B, Krotje C, Nematadzira TG, Nakayiwa F, Ndyanabangi V, Hanley S, Theron G, Violari A, João E, Correa MD, Hofer CB, Navanukroh O, Aurpibul L, Nevrekar N, Zash R, Shapiro R, Stringer JSA, Currier JS, Sax P, Lockman S, IMPAACT 2010/VESTED Study Team.   +28 more
europepmc   +2 more sources

Prospective Analysis of Safety and Efficacy of Tenofovir Alafenamide Fumarate (TAF) in European Real-World Patients with Chronic Hepatitis B: A Single-Centre Real-Word Cohort Study. [PDF]

Pathogens
Background: Tenofovir alafenamide (TAF) is a novel prodrug of tenofovir for the treatment of chronic hepatitis B (CHB) that has shown a favourable renal safety profile while offering suppression of HBV DNA similar to tenofovir disoproxil fumarate (TDF ...
Fülöp B, Fischer J, Hahn M, Böhlig A, Matz-Soja M, Berg T, van Bömmel F.   +6 more
europepmc   +2 more sources

Antiviral Efficacy and Safety of Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate in the Treatment of Chronic Hepatitis B [PDF]

Central Asian Journal of Medical Sciences, 2020
Objectives: To provide compare of the efficacy and safety tenofovir alafenamide (TAF) to tenofovir disoproxil fumarate (TDF) in patients with HBeAg-negative and HBeAg-positive chronic hepatitis B.
Tuvshinbayar Narangerel, Amaraa Ravdan, Gegeebadrakh Baljinnyam, Burmaajav Badrakh, Baatarkhuu Oidov   +4 more
doaj   +3 more sources

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: Two randomised, double-blind, phase 3, non-inferiority trials [PDF]

Lancet, The, 2015
none27siBackground Tenofovir disoproxil fumarate can cause renal and bone toxic effects related to high plasma tenofovir concentrations. Tenofovir alafenamide is a novel tenofovir prodrug with a 90% reduction in plasma tenofovir concentrations. Tenofovir
Andrew K Cheng, Andrew Plummer, Anton Pozniak, Benoit Trottier, Christian Callebaut, Daniel Podzamczer, David Wohl, Edwin DeJesus, Ellen Koenig, Frank Post, Gordon Crofoot, Hal Martin, Huyen Cao, Jaime Andrade-Villanueva, Jean Michel Molina, Joseph M Custodio, Lijie Zhong, Marshall W Fordyce, Melanie Thompson, Michael Saag, Michael T Yin, Paul E Sax, Scott McCallister, Shinichi Oka   +23 more
core   +3 more sources

Efficacy and Safety of Tenofovir Alafenamide Fumarate and Tenofovir Disoproxil Fumarate for Preventing Mother-to-Child Transmission of Hepatitis B in Treatment-Naïve mothers: An Observational Study. [PDF]

Virol J
Mother-to-child transmission (MTCT) is the primary cause of hepatitis B virus (HBV) infection. Antiviral therapy is crucial to reduce MTCT for pregnant women with high viremia.
Yang X, Chen J, Duan L, Li X, Cheng W, Chen Y, Huang Y, Huang Z.   +7 more
europepmc   +2 more sources

Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population

CPT: Pharmacometrics & Systems Pharmacology, 2023
Tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) are prodrugs of the nucleotide analogue tenofovir, which acts intracellularly to inhibit HIV replication.
Aida N. Kawuma, Roeland E. Wasmann, Phumla Sinxadi, Simiso M. Sokhela, Nomathemba Chandiwana, Willem D. F. Venter, Lubbe Wiesner, Gary Maartens, Paolo Denti   +8 more
doaj   +3 more sources

Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate. [PDF]

PLoS ONE, 2019
BackgroundBecause tenofovir alafenamide (TAF) leads to significantly lower plasma tenofovir concentrations than tenofovir disoproxil fumarate (TDF) and is a stronger substrate for P-glycoprotein (P-gp) than TDF, TAF could lead to decreased central ...
Linn Hermansson, Aylin Yilmaz, Richard W Price, Staffan Nilsson, Scott McCallister, Tariro Makadzange, Moupali Das, Henrik Zetterberg, Kaj Blennow, Magnus Gisslen   +9 more
doaj   +6 more sources

Chiral Analysis of the Key Intermediates of Tenofovir Alafenamide Fumarate

Pharmaceutical Fronts, 2023
(R)-Tenofovir phenyl ester ((R)-1) and (R)-tenofovir diphenyl ester ((R)-2) are key intermediates for the practical synthesis of tenofovir alafenamide fumarate, which is a mainstay antiretroviral for the treatment of chronic hepatitis B and HIV-1 ...
Man Li, Ting Zhou, Qing-Wen Zhang
doaj   +2 more sources

Pharmacokinetics of Tenofovir Alafenamide Fumarate and Tenofovir in the Chinese People: Effects of Non-Genetic Factors and Genetic Variations [PDF]

Pharmacogenomics and Personalized Medicine, 2021
Xue Li,1,* Xin-Yi Tan,2,* Xue-Jun Cui,3 Ming Yang,1 Chao Chen,1 Xiao-Yun Chen2 1Phase I Clinical Research Laboratory of Shanghai LongHua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of China ...
Li X, Tan XY, Cui XJ, Yang M, Chen C, Chen XY   +5 more
doaj   +2 more sources

Improvement of hepatic fibrosis after tenofovir disoproxil fumarate switching to tenofovir alafenamide for three years. [PDF]

World Journal of Hepatology
BACKGROUND: Both tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) are the first-line treatments for chronic hepatitis B (CHB). We have showed switching from TDF to TAF for 96 weeks resulted in further alanine aminotransferase (ALT ...
Bui, Delana, Hu, Ke-Qin, Huynh, Tung, Zhou, Tina   +3 more
core   +4 more sources